Linezolid shown effective against gram-positive bacteria


Linezolid CAS 165800-03-3Linezolid is a synthetic antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics. A member of the oxazolidinone class of drugs, Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). MRSA is especially troublesome in hospitals where patients with open wounds, invasive devices and weakened immune systems are at greater risk of infection than the general public. The main indications of Linezolid are infections of the skin and soft tissues and pneumonia (particularly hospital-acquired pneumonia), although off-label use for a variety of other infections is becoming popular.

LGM Pharma is a preferred supplier of this synthetic antibiotic for research and development purposes. Inquire about Linezolid CAS #165800-03-3 prices, availability, delivery, purity and more.

Linezolid was the first commercially available oxazolidinone antibiotic approved for use in 2000 by the Food and Drug Administration (FDA). Linezolid is marketed by Pfizer under the trade names Zyvox (in the US, UK, Australia, and several other countries). Linezolid is also marketed under the trade names Zyvoxid (in EU), and Zyvoxam (in Canada and Mexico). Generics are also available in India, such as Linospan (Cipla).

Linezolid Resistance

Initially there was hope that bacteria would be unable to develop resistance to Linezolid. However, in 2001 Staphylococcus aureus was first identified as being resistant to Linezolid. The five patients infected with vancomycin-resistant Enterococcus faecium (VREF) were treated in three Chicago area hospitals. The patients received Linezolid but then showed signs of emergent resistance to treatment. Resistance arose after about three to six weeks of therapy with Linezolid, which is used to treat VREF infections. Unfortunately, two of the five patients with Linezolid resistant Staphylococcus aureus (LRSA) died.

The first known outbreak occurred during a 13-week period in 2008 in a hospital in Madrid, Spain. The outbreak of LRSA was recently featured in the Journal of the American Medical Association (JAMA). Reduction of Linezolid use and infection-control measures were associated with the termination of the outbreak.

Resistance to the drug is extremely uncommon in Staphylococcus aureus (Staph Infections). Linezolid is widely used in critical care facilities because of its broad antimicrobial spectrum, favorable short-term safety profile, and its effectiveness against severe MRSA infections.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: